he US Food and Drug Administration (FDA) has granted approval for Dilon Technologies’ MarginProbe 2, a next-generation intraoperative margin assessment device for use in breast cancer surgery, enabling its American launch.

The device is intended to assist surgeons during breast-conserving surgery, to decrease repeat procedures and enhance outcomes for patients.

It builds upon the original MarginProbe, which is already in use for margin assessment in real-time.